Background Meropenem is an anti-Gram-negative antimicrobial, the time-dependent activity of which may be maximized through administration by continuous infusion. Objectives The objectives of this study were to characterize the pharmacokinetics of continuous infusion meropenem in relation to body size and Cockcroft-Gault estimated creatinine clearance (CL CR ) in overweight and obese patients with stable and unstable kidney function with the intent of creating a nomogram for optimal dosing. Patients and Methods Patients from a single institution with a body mass index C25 kg/m 2 receiving meropenem by continuous infusion with measurement of meropenem steady-state concentrations (C ss ) were identified. Individual Bayesian estimates of meropenem volume of distribution of the central compartment (V c ) and clearance (CL) were calculated and relationships to body size descriptors and CL CR estimated using these body size descriptors were defined by regression. Kidney function stability was defined based on median absolute deviation, stratification by the ratio of maximum to minimum serum creatinine (SCr) and individual patient-level regression of SCr over time. The influence of kidney function stability on meropenem CL estimation by CL CR was tested. Results A total of 375 patients (77.9 % male) with 846 C ss values (62.4 % of patients with C2 measurements) were identified. The median daily dose of meropenem and frequency of infusion bag changes were 2000 mg/day and four times per day, respectively. The meropenem C ss values were C16, C8, C4, and C2 mg/L for 41.1, 76.1, 97.4, and 99.9 % of observations, respectively. The median (range) age, weight, and BMI were 66 (24-90) years, 90 (70-250) kg, and 30.8 (25.1-81.6) kg/m 2 , respectively. The mean [standard deviation (SD)] serum creatinine at baseline was 1.57 (1.37) mg/dL. The mean (SD)
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The influence of kidney function stability on meropenem CL estimation by CL CR was tested. Results A total of 375 patients (77.9 % male) with 846 C ss values (62.4 % of patients with C2 measurements) were identified. The median daily dose of meropenem and frequency of infusion bag changes were 2000 mg/day and four times per day, respectively. The meropenem C ss values were C16, C8, C4, and C2 mg/L for 41.1, 76.1, 97.4, and 99.9 % of observations, respectively. The median (range) age, weight, and BMI were 66 (24-90) years, 90 (70-250) kg, and 30.8 (25.1-81.6) kg/m 2 , respectively. The mean [standard deviation (SD)] serum creatinine at baseline was 1.57 (1.37) mg/dL. The mean (SD) V c was 28.1 (1.36) L and not related to body size, while CL was 8.85 (6.40 ) L/h and best related to CL CR estimated using adjusted body weight (ABW). The meropenem CL to CL CR relationship was not significantly impacted by the presence or absence of kidney function stability. The user-friendly dosing nomogram based on CL CR estimated using ABW showed that optimal drug exposure [C ss C minimum inhibitory concentration (MIC)] may be obtained even against multi-drug resistant (MDR) pathogens when considering dosages up to 1250 mg every 6 h by continuous infusion. Conclusions Meropenem CL is best estimated using CL CR with ABW in patients with a BMI C25 kg/m 2 and this relationship is not altered by unstable kidney function. Application of our dosing nomogram may improve the care of overweight and obese patients with severe MDR Gramnegative infections treated with meropenem by continuous infusion.
Key Points
Meropenem is a major anti-Gram-negative antimicrobial whose time-dependent activity in the treatment of severe infection due to nosocomial pathogens with borderline susceptibility may be maximized by continuous infusion.
The current study shows that an empiric fivecategory daily dose regimen of meropenem by continuous infusion (250 mg every 6 h, 500 mg every 6 h, 1000 mg every 8 h, 1000 mg every 6 h, 1250 mg every 6 h) stratified by creatinine clearance based on adjusted body weight is expected to have a [90 % probability of achieving effective therapeutic exposure in patients with a BMI C25 kg/m 2 , regardless of stability of renal function.
Introduction
The worldwide prevalence of adults with a body mass index (BMI) [25 kg/m 2 is now 36.9 % in men and 38 % in women [1] . This increased prevalence of overweight and obese individuals over a 33-year period has important clinical implications [1] . Increased adiposity can require modifications of drug dosing strategies because obesity induces physiologic effects that impact host response as well as the pharmacology of some drugs [2] . Specifically, obesity can induce glomerular hyperfiltration that enhances the renal clearance (CL) of several antimicrobials such as the b-lactams [3, 4] . Estimation of this enhanced renal CL is often dependent on the estimation of creatinine clearance (CL CR ) as an aid for antimicrobial dosing [5] . The Cockcroft-Gault equation is most often used to estimate CL CR and is based on age, sex, SCr, and total body weight (TBW) as a scalar [6] . Kidney function does not scale proportionately with TBW and its estimation using the Cockcroft-Gault equation is less reliable in obese patients [5] . This is problematic because dosing nomograms for certain antimicrobials such as meropenem are stratified by the estimated CL CR [7] .
Meropenem is a major intravenously administered antimicrobial with activity against several nosocomial Gramnegative pathogens [8] . Like most b-lactams, time above the minimum inhibitory concentration (MIC) (T [ MIC) is the pharmacokinetic-pharmacodynamic index predictive of meropenem antimicrobial effects [9] . This pharmacokinetic-pharmacodynamic profile supports achievement of a sustained meropenem concentration above a threshold value, which occurs most optimally by continuous infusion against key pathogens such as Pseudomonas aeruginosa [10] . This may be extremely relevant when treating infections due to bacterial pathogens with borderline susceptibility to or even with in vitro resistance to meropenem [11, 12] . However, early concerns about the chemical stability of meropenem intravenous solutions at room temperature hindered the adoption of this continuous infusion dosing modality [8, 13] . Recent work from research groups including ours demonstrate that meropenem is sufficiently stable for 6-8 h at 25-35°C, which permits continuous infusion administration by replacing the intravenous bag three to four times a day [13] [14] [15] . Our group has defined and validated a dosing nomogram for the administration of meropenem by continuous infusion in patients with severe Gram-negative infection based on CL CR [7] .
This previous work included primarily normal-weight and overweight individuals and a limited number of obese individuals. In addition, this prior work included patients with stable renal function which served as an excellent covariate of inter-individual variability [7] . Critically ill patients have a dynamic profile of renal function that can be in an augmented or decompensated state which can either return to baseline or decline below baseline over the treatment course [16] . This marked intra-individual variability in CL CR presents a significant challenge to clinicians who wish to optimize the dose of meropenem. Limited access to a meropenem assay requires a better understanding of the inter-relationship between changing CL CR within patients and meropenem pharmacokinetics to aid personalized antimicrobial dosing.
In order to address this significant clinical issue, we sought to first determine the relationship of meropenem pharmacokinetic parameters to body size and CL CR . Our secondary objective was to ascertain the influence of changes in CL CR on the estimation of meropenem CL. The final intent was to create a practical dosing nomogram of meropenem by continuous infusion, which may enable optimal drug exposure in the treatment of overweight and obese patients with severe Gram-negative infections.
Patients and Methods

Study Design
This investigation was approved by the Ethics Committee of the Santa Maria della Misericordia University Hospital, Udine, Italy. Therapeutic drug monitoring (TDM) of meropenem has been routinely performed at our institution for dose optimization for several years. Our empiric meropenem continuous infusion approach is based on translation of the patient's estimated CL CR to an intravenous infusion rate based on a nomogram that we have previously validated [7] . The empiric dose is selected to target desired steady-state concentrations (C ss ) between 8 and 12 mg/L. The rationale behind this empiric meropenem C ss range is based on the EUCAST (European Committee on Antimicrobial Susceptibility Testing) clinical breakpoint for meropenem against Enterobacteriaceae of 2 mg/L and the desire to maintain a C ss /MIC ratio of 4-6 above this threshold value [7, 17] . Previous studies have suggested that this approach maximizes the probability for clinical efficacy while minimizing the risk of emergence of resistance [17] [18] [19] . As a result, critically ill patients treated with meropenem administered by continuous infusion, both empirically and for documented Gram-negative infections, were included in this investigation. The C ss data included in this analysis were obtained from patients treated with continuous infusion of meropenem at unmodified dosages for at least 2 days. In light of the short-term stability of meropenem in an aqueous solution at room temperature, each meropenem dose was replaced with a freshly prepared infusion bag every 6 h and up to 8 h in rare cases.
In order to avoid inaccuracy of CL CR estimates, patients bedridden for a long time (C21 days) and/or undergoing any kind of renal replacement therapies were excluded from this analysis. Patient demographic information, meropenem dosing and dose timing information, and sample collection and time of collection information were extracted from the medical record.
Meropenem Assay
Meropenem plasma concentrations were analyzed using a validated high-performance liquid chromatography (HPLC) method with UV detection, as previously described [7] . Briefly, for meropenem extraction, 25 lL of a 1 lg/lL cefepime solution was added as an internal standard to 1 mL of calibration, quality control, or patient sample, which was then mixed and transferred into an extraction cartridge conditioned with 2 mL of methanol and then with 2 mL of 0.05 M phosphate buffer at pH 4. The extraction cartridge was then washed with 2 mL of 0.05 M phosphate buffer at pH 4, the sample was eluted with 800 lL of a solution of 0.05 M phosphate buffer (pH 6)-methanol (9:1, vol/vol), and then 20 lL of the eluate was injected into the HPLC system (125S Beckman HPLC system coupled with Beckman 166 UV detector; Beckman Instruments, Berkeley, CA, USA). Separation was carried out through an Ultrasphere C18 column (octyldecyl saline, 250 mm by 4.6 mm by 5 lm; Beckman, Berkeley, CA, USA) with a solution of phosphate buffer-acetonitrile (91:9, vol/vol) at a flow rate of 1.2 mL/min in isocratic conditions (cefepime and meropenem retention times were 3.8 and 9.1 min, respectively). Precision and accuracy were assessed by performing replicate analyses of quality control samples against calibration standards. Intra-and inter-assay coefficients of variation (CVs) were always less than 10 %. The lower limit of detection was 0.5 mg/L.
Pharmacokinetic Analyses
Pharmacokinetic systems analysis was performed using ADAPT 5 (BMSR, Los Angeles, CA, USA). A one-compartment model with zero-order input and first-order output was used to fit the data by the maximum likelihood expectation maximization (MLEM) algorithm with importance sampling set to 2000 per iteration. The observed data were weighted by the reciprocal of variance. Models of higher complexity were not deemed necessary given that single sample measurements were obtained around each dosing period. After this initial approach, individual Bayesian estimates of the volume of distribution of the central compartment (V c ) and CL were computed for each observed concentration-time value. This was achieved using the generated population mean V c and CL and the variance and covariance information (using the entire dataset) as the prior by the Maximum a posteriori Bayesian (MAP-Bayesian) method for individual data fitting. The individual pharmacokinetic analysis was performed with the respective associated meropenem doses using (1) the entire concentration-time dataset; (2) first observation concentration-time data only; and (3) last observation concentration-time data only. Given that the meropenem pharmacokinetic parameters could change with time in patients with unstable CL CR , each concentration-time point was fit by depleting the individual data file of concentration-time information before and after the timepoint of interest. Once these covariate relationships were defined, Monte-Carlo simulations based on log-normal distributions (n = 10,000 per CL CR category) were used to estimate the probability of achieving C ss values above meropenem MIC threshold values based on practical dosing considerations by CL CR category.
Statistical Analyses
Descriptive statistics were used to present demographic information. Equations to compute body surface area (BSA by Mosteller's adaptation), ideal body weight (IBW), adjusted body weight (ABW), and lean body weight (LBW) were used to transform height (cm) and TBW (kg) data by sex based on the respective equation (Eqs. 1, 2, 3, and 4) [20] [21] [22] [23] . The weight descriptors IBW, ABW, and LBW were substituted for TBW in the Cockcroft-Gault equation, as previously described, and CL CR was normalized to BSA [5] . To evaluate kidney function stability, a series of approaches were employed. The median absolute deviation of serum creatinine (SCr) was computed for each patient across the respective observation period and a value of zero was used to define patients as having 'stable' kidney function. The minimum and maximum SCr was identified for each patient and the ratio of the two used to stratify the population. The SCr values were regressed over time for each individual patient and those with a non-significant slope deemed 'no change'. Those with a significant positive slope were deemed 'rising SCr' and those with a significant negative slope as 'declining SCr'. The relationship of V c and CL to demographic variables and body size descriptors was evaluated visually by matrix plots and Pearson's correlation coefficients. Ordinary least squares regression was used to identify covariates associated with V c and CL and transformations were applied based on the residual versus fitted plots. The relationships were evaluated based on the groups defined as having stable and unstable kidney function. Significance was based on a p value\0.05 and all aforementioned analyses were executed using STATA/SE Ò version 13.1 (Stata Corp., College Station, TX, USA).
Results
Patient Demographics
A total of 375 patients were included in this analysis and were predominantly male (77.9 %). 
Estimated Creatinine Clearance
The mean [standard deviation (SD)] SCr and CL CR using TBW at baseline were 1.57 (1.37) mg/dL and 97.0 (67.4) mL/min. The mean (SD) BSA-normalized CL CR was 77.5 (51.1) mL/min/1.73 m 2 , and 12 % of patients had augmented renal CL defined as a CL CR [ 130 mL/min/ 1.73 m 2 at baseline. When considering all observed data by patient, 46.7 % of patients had a median absolute deviation of SCr of zero, indicating no change across the treatment course. The ratio of the maximum to minimum SCr value was \1.25 in 73.6 %, 1.25 to \1.50 in 13.3 %, 1.50 to \2.00 in 5.88 %, and C2.00 in 7.22 % of the observed sample. For the direction of SCr change over time, 131 patients had a declining SCr value, of whom 42 (32.1 %) had a C1.5-fold decline. In contrast, 69 patients had a rising SCr value, of whom 14 (20.2 %) had a C1.5-fold rise. Overall, the data indicated an almost equal balance in the population with stable and unstable kidney function.
Meropenem Dosing and Concentration Data
The median (range) daily dose and frequency of infusion bag changes was 2000 (375-6000) mg/day and four (three to six) times per day, respectively. The modal daily dose was 2000 mg/day (42 % of patients) and 82 % of daily continuous infusion doses were administered by replacing the infusion bag four times per day. A total of 846 meropenem concentrations were measured, and the distribution of observed values is illustrated in Fig. 1 . The median (5th, 95th percentile) meropenem C ss values were 11.9 [4.93, 34.9] mg/L. The meropenem C ss values were C16, C8, C4, and C2 mg/L for 41.1, 76.1, 97.4, and 99.9 % of observations. The proportion of patients by number of samples measured was 37.6 % (n = 1), 30.9 % (n = 2), 16.3 % (n = 3), 6.67 % (n = 4), 4.80 % (n = 5), and 3.73 % (n [ 5).
Meropenem Pharmacokinetic Relationships
The base structural model provided an excellent fit to the data (R 2 = 0.977). As shown in Fig. 2 (6.31 ) L/h, and 9.14 (6.39) L/h based on all observations, restricted to first observation, and restricted to last observation, respectively. As shown, the central tendency of V c was not altered by observation restriction and the CV was less than 5 %. In contrast, the central tendency of CL was altered by observation restriction and the CV was between 70 and 77 %.
No significant relationships were identified when comparing V c to age, weight, height, BMI, BSA, IBW, ABW, or LBW. Meropenem CL was correlated to CL CR using TBW (R = 0.545), and the relationship to the individual continuous variable components of CL CR were SCr (R = -0.444), age (R = -0.337), and weight (R = 0.164). Elimination of TBW from the CL CR equation changed the relationship to CL marginally (R = 0.542). For the alternate body size scalars, BSA had the 'best' relationship to CL (R = 0.201) and also marginally changed the relationship of CL to CL CR when normalized to BSA (R = 0.547). The relationship of CL to CL CR using alternate weight descriptors was 'best' with the use of ABW but was overall (R = 0.557) marginally different from that presented.
Regression of CL to CL CR , CL CR normalized to BSA, and CL CR using ABW were significant and yielded R 2 values of 0.297, 0.299, and 0.310. The residual versus fitted plots demonstrated that the models were unbiased but heteroscedastic, with variance of residuals increasing with CL. Natural logarithm transformation improved the relationship between CL and CL CR , which was 'best' with CL CR using ABW (R 2 = 0.494). Figure 3a , b illustrates the relationship of Ln(CL) to Ln(CL CR using ABW) and demonstrates that the model is unbiased and homoscedastic. The mean (95 % CI) for the coefficient of the slope and intercept for this relationship is 0.777 (0.723-0.831) and -1.41 (-1.64 to -1.18). Inclusion of the direction of SCr change (-1, 0, and 1) into the model was not a significant (p = 0.083) covariate of the relationship between Ln(CL) and Ln(CL CR using ABW). Meropenem CL changed with CL CR , and this relationship is illustrated for patients with a C1.5 fold rise in SCr (declining CL) or a C1.5 fold decline in SCr (rising CL). Using the definition of a median absolute deviation of zero for SCr as representative of stable kidney function, we observed no meaningful change in the relationship between Ln(CL) and Ln(CL CR using ABW). 
Meropenem Dosing Nomogram
The relationship of meropenem CL to CL CR estimated using ABW was used to simulate C ss values expected with meropenem regimens that could be practicably delivered as 750-5000 mg/day in three to four intervals. The simulation included generation of distributions with truncation for each category such that median (range) CL CR by category was: 20 (10.6-29.8) mL/min, 40.0 (30.1-49.9) mL/min, 69.2 (50.5-79.9) mL/min, 99.7 (80.0-119.9) mL/min, and 150 (120-199.9) mL/min. Table 2 provides estimated probabilities for achieving meropenem C ss thresholds for two potential meropenem dosing nomograms. The first nomogram (750-4000 mg/day) predicted a 100 % probability of achieving C ss values above 8 lg/mL but below 20 % for 16 lg/mL. The second higher-dose tiered nomogram of 1000-5000 mg/day increased the probability of achieving C ss values at or above 16 lg/mL. Although higher daily doses of meropenem may be needed for the 10-30 mL/min and 120-200 mL/min category for a 16 lg/mL threshold, all simulated C ss values for nomogram 2 were [12 lg/mL.
Discussion
Meropenem is a critical antimicrobial agent that is employed empirically and for documented cases of severe Gram-negative infections [7] . Its use has expanded beyond its approved indications of skin and skin structure infections (up to 1.5 g/day), intra-abdominal infections (up to 3 g/day), and bacterial meningitis in pediatric patients C3 months of age (up to 6 g/day) [8] . Also, the approach to dosing of meropenem has evolved substantially since its regulatory approval almost 20 years ago. Specifically, the recommendations for short infusions over 15-30 min have been superseded in clinical practice by protocols for extended infusion and continuous infusion [7] [8] [9] [10] . The underlying rationale for this change in infusion rate has been to optimize the T [ MIC profile of meropenem, which is not achieved by short intermittent infusion in some settings [9, 10, 25] , especially when treating critically ill patients [26] . Furthermore, the concerns regarding insufficient chemical stability to permit such optimization have been alleviated by data from several groups [13] [14] [15] . These stability data have also been extended beyond the reference-listed drug to encompass generic formulations of meropenem [13] [14] [15] . Given that the primary route of meropenem elimination is through the kidneys, nomograms to define meropenem daily doses have been developed based on CL CR estimated using the Cockcroft-Gault equation [7] . The product label for meropenem also recommends this equation, which relies on body weight as a parameter [8] . However, TBW over-estimates CL CR in overweight and obese individuals, who are increasingly common globally [5] . In addition, estimation of CL CR relies on a point estimate of SCr and the underlying principles of this equation require this parameter to be stable when used to estimate CL CR [6] . Unfortunately, unstable SCr values are common in the acute care setting, which further complicates estimation of drug dosing for agents such as meropenem [16] .
Hence, this investigation was performed to gain a better appreciation for the relationship of CL CR and meropenem CL in overweight and obese patients with stable and unstable kidney function who received meropenem by continuous infusion. To our knowledge, ours is the first study which has assessed the pharmacokinetic-pharmacodynamic profile of meropenem by continuous infusion in a very large sample of patients with a BMI C25 kg/m 2 that included a wide weight distribution, with approximately one-third of patients over 100 kg. Our pharmacokinetic findings are at least partially in agreement with the pharmacokinetic parameters estimated in limited samples of morbidly obese patients receiving meropenem by intermittent infusion [25, 27] .
The mean estimated CL CR was reduced by 20 % with BSA normalization that was consistent with the aforementioned overestimation problem in this population. As expected from previous analyses, the CL of meropenem was predicted by estimated CL CR . However, we demonstrated that weight was the least important parameter in that equation. More specifically, exclusion of weight from the Cockcroft-Gault equation, for example, resulted in a relatively comparable model. Use of alternate weight descriptors in CL CR estimation had a marginal impact on the prediction of CL, but in relative terms use of ABW was the best of those tested. This relationship was unbiased and homoscedastic when represented by logarithm transformation such that Ln CL in L=h ð Þ¼0:777Â Ln CL CR ABWinmL=min ð Þ À 1:41. Estimation of CL by this method permits computation of the rate of infusion (R 0 ) because R 0 = C ss 9 CL, where C ss can be specified by the desired target value. However, it is important to appreciate that this model can only explain approximately 50 % of the inter-individual variability in meropenem CL. A more accurate estimate of individual meropenem CL can be computed through measurement of meropenem C ss .
Given the absence of a meropenem assay in most institutions, estimated CL CR defaults as the next best approach to optimize meropenem dosing. A fundamental limitation of CL CR estimation is the requirement for a stable SCr value that is not often present. We demonstrate in our population of evaluated patients that 53.3 % had unstable SCr using the median absolute deviation and regression as a tool to define this instability. Our data analysis demonstrates that although CL CR may not necessarily reflect kidney function when SCr is unstable, it does reflect meropenem CL. In simple terms, the change in CL CR tracks with the change in meropenem CL, and this means that the meropenem CL to CL CR relationship is not significantly impacted by the presence or absence of kidney function stability. So, a point estimate of CL CR provides a reasonable point estimate of meropenem CL.
Our results provide important insights for clinicians who wish to optimize the dosing of meropenem by continuous infusion in overweight and obese patients. This might be especially relevant for patients at high risk of infections due to pathogens with borderline susceptibility to meropenem, especially when a timely assay is not available to permit dose modification.
Practical meropenem continuous infusion dosing nomograms based on CL CR categories using ABW were created in line with our practice of targeting C ss values that are 4-6 times higher than the clinical breakpoint. Nomogram 2 shows that an empiric five-category daily dose regimen by continuous infusion (250 mg every 6 h, 500 mg every 6 h, 1000 mg every 8 h, 1000 mg every 6 h, 1250 mg every 6 h) is expected to have a [90 % probability of achieving effective therapeutic exposure with meropenem in patients with a BMI C25 kg/m 2 , regardless of stability of renal function. Although for nomogram 2 the probabilities for achieving a C ss value above 16 lg/mL are Considering that this dosing nomogram may allow a target C ss of up to 16 lg/mL, it is noteworthy that its application in clinical practice could be deemed helpful even for the treatment of infections caused by multi-drug resistant (MDR) Gram-negative pathogens resistant to meropenem, such as Acinetobacter baumannii, P. aeruginosa, and carbapenemase-producing Klebsiella pneumoniae with an MIC for meropenem higher than the clinical breakpoint of 2 lg/mL. It has been suggested that administration by extended or continuous infusion of time-dependent antibacterials with Gram-negative activity, by maintaining drug concentrations above the MIC for most of the dosing interval, can overcome resistance associated with MDR Gram-negative bacteria [12, 28, 29] . Several authors consider that for meropenem this strategy may be conceivable against pathogens with a meropenem MIC of up to 8 mg/L, provided that combination therapy with another anti-Gram-negative active agent is pursued [12, 28, 30] . Interestingly, our nomogram suggests that administration of dosages up to 1250 mg every 6 h by continuous infusion could ensure maintenance of a C ss higher than 12 mg/L for 24 h a day.
These important insights should be considered along with key limitations of this study design. The data were acquired retrospectively and so bear the assumption that the information recorded in the medical record pertaining to times of dosing and sample collected were accurate. The sample included primarily male patients, and a clear explanation for this gender imbalance is not known. In addition, the concentration-time information was based on a single C ss measurement across a daily dosing interval. This sampling strategy and dosing modality likely contributed to similar V c estimates across the population and negated the ability to identify body size as a covariate of V c . Finally, the definition of stability based on regression analyses assumed linear trends that may not have been the case. However, use of median absolute deviation as a metric identified the same individuals as having stable and unstable kidney function which sufficiently addresses this limitation.
Conclusions
Meropenem is a critical antimicrobial agent in our armamentarium against serious Gram-negative pathogens. The dosing of this agent can be optimized by continuous infusion, with a daily dose and rate of infusion that can be estimated using CL CR with ABW for patients with a BMI C25 kg/m 2 . Furthermore, the dosing of this agent is expected to be modifiable in patients with improving or declining kidney function. Validation of the results by other independent groups for meropenem and extension of this approach to other time-dependent antimicrobials with renal elimination could improve the care of overweight and obese patients with severe infections, especially when TDM is not available in a practical manner.
